Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5477 Glen Lakes Drive, #100, Dallas, TX 75234, USA.
Curr Treat Options Neurol. 2006 Sep;8(5):367-75. doi: 10.1007/s11940-006-0026-6.
Patients with neurologic disorders commonly experience sleep dysfunction and psychiatric disorders. The most common sleep dysfunction is insomnia, which is a primary symptom in 30% to 90% of psychiatric disorders. Insomnia and fatigue are prominent symptoms of anxiety disorders and major depression, including patients who are treated but have residual symptoms. Anxiety and depressive disorders account for 40% to 50% of all cases of chronic insomnia. It is also recognized that primary insomnia and other primary sleep disorders produce symptoms that are similar to those reported by patients with psychiatric disorders. A clinician must judge whether sleep deprivation causes mood disturbance or whether depressive or anxiety disorder represents the primary reason for sleep dysfunction. When insomnia is comorbid with mild to moderate depression, therapy should begin with bedtime dosing of sedating antidepressants such as mirtazapine, nefazodone, or tricyclic antidepressants, which are preferred because of their sedative effects, although side effects may limit their usefulness. Intervention for chronic insomnia is similar in nonpsychiatric and psychiatric patients. Behavioral therapies, particularly cognitive behavioral therapy, and lifestyle changes show significant long-term efficacy as treatments for chronic insomnia. Sedative hypnotic agents are the most studied agents to treat insomnia, particularly those that are active through the benzodiazepine receptor-GABA complex, such as benzodiazepines, eszopiclone, zaleplon, and zolpidem. The new melatonin-receptor agonist ramelteon has not yet been studied in psychiatric patients. Prescription of adjunctive trazodone 50 to 150 mg is a common clinical practice to treat comorbid insomnia during antidepressant therapy, but published data are surprisingly limited when considered against the frequent usage of trazodone. Although there has been insufficient research on the use of atypical antipsychotic agents in severe insomnia, psychiatrists use quetiapine, olanzapine, or other agents to lessen agitation that disrupts sleep onset or maintenance. When insomnia or hypersomnia continues even as mood, anxiety, or thought disorders improve with standard therapy, the physician should consider the potential presence of underlying sleep disorders.
患有神经障碍的患者通常会经历睡眠功能障碍和精神障碍。最常见的睡眠功能障碍是失眠,它是 30%到 90%精神障碍的主要症状。失眠和疲劳是焦虑症和重度抑郁症的突出症状,包括经治疗但仍有残留症状的患者。焦虑症和抑郁症占所有慢性失眠病例的 40%到 50%。人们还认识到,原发性失眠和其他原发性睡眠障碍产生的症状与精神障碍患者报告的症状相似。临床医生必须判断是睡眠剥夺导致情绪紊乱,还是抑郁或焦虑障碍是睡眠功能障碍的主要原因。当失眠与轻度至中度抑郁共病时,治疗应从睡前给予镇静抗抑郁药开始,如米氮平、奈法唑酮或三环类抗抑郁药,由于其镇静作用,这些药物被优先选用,尽管副作用可能会限制其用途。非精神科和精神科患者的慢性失眠干预措施相似。行为疗法,特别是认知行为疗法和生活方式改变,作为慢性失眠的治疗方法具有显著的长期疗效。镇静催眠药是研究最多的治疗失眠的药物,特别是那些通过苯二氮䓬受体- GABA 复合物发挥作用的药物,如苯二氮䓬类、右佐匹克隆、扎来普隆和唑吡坦。新型褪黑素受体激动剂雷美尔酮尚未在精神科患者中进行研究。在抗抑郁治疗期间,开处方辅助性曲唑酮 50 至 150 毫克是一种常见的临床实践,用于治疗共病性失眠,但考虑到曲唑酮的频繁使用,相关的已发表数据却令人惊讶地有限。尽管在严重失眠中使用非典型抗精神病药物的研究不足,但精神科医生会使用喹硫平、奥氮平或其他药物来减轻扰乱入睡或维持睡眠的激越。当即使情绪、焦虑或思维障碍通过标准治疗得到改善后,失眠或嗜睡仍持续存在时,医生应考虑潜在的睡眠障碍的存在。